Cargando…
Neurosensory dysfunction: A diagnostic marker of early COVID-19
OBJECTIVE: To describe neurosensory dysfunctions, including hyposmia, hypogeusia, and tinnitus, in patients with COVID-19. METHODS: Clinical characteristics and oropharyngeal swabs were obtained from 86 patients with COVID-19 hospitalized in Guangzhou Eighth People’s Hospital. The chronological anal...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323654/ https://www.ncbi.nlm.nih.gov/pubmed/32615326 http://dx.doi.org/10.1016/j.ijid.2020.06.086 |
_version_ | 1783551809013415936 |
---|---|
author | Liang, Yujie Xu, Jiabin Chu, Mei Mai, Jianbo Lai, Niangmei Tang, Wen Yang, Tuanjie Zhang, Sien Guan, Chenyu Zhong, Fan Yang, Liuping Liao, Guiqing |
author_facet | Liang, Yujie Xu, Jiabin Chu, Mei Mai, Jianbo Lai, Niangmei Tang, Wen Yang, Tuanjie Zhang, Sien Guan, Chenyu Zhong, Fan Yang, Liuping Liao, Guiqing |
author_sort | Liang, Yujie |
collection | PubMed |
description | OBJECTIVE: To describe neurosensory dysfunctions, including hyposmia, hypogeusia, and tinnitus, in patients with COVID-19. METHODS: Clinical characteristics and oropharyngeal swabs were obtained from 86 patients with COVID-19 hospitalized in Guangzhou Eighth People’s Hospital. The chronological analysis method was used to detail neurosensory dysfunction. The cycle threshold (Ct) values were used to approximately indicate viral load. RESULTS: Forty-four (51.2%) patients had neurosensory dysfunction: hyposmia (34, 39.5%), hypogeusia (33, 38.4%), and tinnitus (three, 3.5%). Neurosensory dysfunction was significantly more common in patients under 40 years old (p = 0.001) and women (p = 0.006). Hyposmia and hypogeusia coexisted in 23 (26.7%) patients. The interval between onset of hyposmia and hypogeusia was 0.7 ± 1.46 days. The interval from onset of hyposmia and hypogeusia to typical COVID-19 symptoms was 0.22 ± 4.57 and 0.75 ± 6.77 days; the interval from onset of hyposmia and hypogeusia to admission was 6.06 ± 6.68 and 5.76 ± 7.68 days; and the duration of hyposmia and hypogeusia was 9.09 ± 5.74 and 7.12 ± 4.66 days, respectively. The viral load was high following symptoms onset, peaked within the first week, and gradually declined. CONCLUSIONS: Neurosensory dysfunction tends to occur in the early stage of COVID-19, and it could be used as a marker for the early diagnosis of COVID-19. |
format | Online Article Text |
id | pubmed-7323654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73236542020-06-30 Neurosensory dysfunction: A diagnostic marker of early COVID-19 Liang, Yujie Xu, Jiabin Chu, Mei Mai, Jianbo Lai, Niangmei Tang, Wen Yang, Tuanjie Zhang, Sien Guan, Chenyu Zhong, Fan Yang, Liuping Liao, Guiqing Int J Infect Dis Article OBJECTIVE: To describe neurosensory dysfunctions, including hyposmia, hypogeusia, and tinnitus, in patients with COVID-19. METHODS: Clinical characteristics and oropharyngeal swabs were obtained from 86 patients with COVID-19 hospitalized in Guangzhou Eighth People’s Hospital. The chronological analysis method was used to detail neurosensory dysfunction. The cycle threshold (Ct) values were used to approximately indicate viral load. RESULTS: Forty-four (51.2%) patients had neurosensory dysfunction: hyposmia (34, 39.5%), hypogeusia (33, 38.4%), and tinnitus (three, 3.5%). Neurosensory dysfunction was significantly more common in patients under 40 years old (p = 0.001) and women (p = 0.006). Hyposmia and hypogeusia coexisted in 23 (26.7%) patients. The interval between onset of hyposmia and hypogeusia was 0.7 ± 1.46 days. The interval from onset of hyposmia and hypogeusia to typical COVID-19 symptoms was 0.22 ± 4.57 and 0.75 ± 6.77 days; the interval from onset of hyposmia and hypogeusia to admission was 6.06 ± 6.68 and 5.76 ± 7.68 days; and the duration of hyposmia and hypogeusia was 9.09 ± 5.74 and 7.12 ± 4.66 days, respectively. The viral load was high following symptoms onset, peaked within the first week, and gradually declined. CONCLUSIONS: Neurosensory dysfunction tends to occur in the early stage of COVID-19, and it could be used as a marker for the early diagnosis of COVID-19. The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020-09 2020-06-29 /pmc/articles/PMC7323654/ /pubmed/32615326 http://dx.doi.org/10.1016/j.ijid.2020.06.086 Text en © 2020 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Liang, Yujie Xu, Jiabin Chu, Mei Mai, Jianbo Lai, Niangmei Tang, Wen Yang, Tuanjie Zhang, Sien Guan, Chenyu Zhong, Fan Yang, Liuping Liao, Guiqing Neurosensory dysfunction: A diagnostic marker of early COVID-19 |
title | Neurosensory dysfunction: A diagnostic marker of early COVID-19 |
title_full | Neurosensory dysfunction: A diagnostic marker of early COVID-19 |
title_fullStr | Neurosensory dysfunction: A diagnostic marker of early COVID-19 |
title_full_unstemmed | Neurosensory dysfunction: A diagnostic marker of early COVID-19 |
title_short | Neurosensory dysfunction: A diagnostic marker of early COVID-19 |
title_sort | neurosensory dysfunction: a diagnostic marker of early covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323654/ https://www.ncbi.nlm.nih.gov/pubmed/32615326 http://dx.doi.org/10.1016/j.ijid.2020.06.086 |
work_keys_str_mv | AT liangyujie neurosensorydysfunctionadiagnosticmarkerofearlycovid19 AT xujiabin neurosensorydysfunctionadiagnosticmarkerofearlycovid19 AT chumei neurosensorydysfunctionadiagnosticmarkerofearlycovid19 AT maijianbo neurosensorydysfunctionadiagnosticmarkerofearlycovid19 AT lainiangmei neurosensorydysfunctionadiagnosticmarkerofearlycovid19 AT tangwen neurosensorydysfunctionadiagnosticmarkerofearlycovid19 AT yangtuanjie neurosensorydysfunctionadiagnosticmarkerofearlycovid19 AT zhangsien neurosensorydysfunctionadiagnosticmarkerofearlycovid19 AT guanchenyu neurosensorydysfunctionadiagnosticmarkerofearlycovid19 AT zhongfan neurosensorydysfunctionadiagnosticmarkerofearlycovid19 AT yangliuping neurosensorydysfunctionadiagnosticmarkerofearlycovid19 AT liaoguiqing neurosensorydysfunctionadiagnosticmarkerofearlycovid19 |